We presented new data evaluating our investigational therapy in gynecologic oncology at the ESMO - European Society for Medical Oncology Congress. Our latest data underscore our commitment to deliver on our vision and accelerate our late-stage pipeline of antibody medicines for patients seeking potential new options. Read more: http://gmab.ly/aNZi50X1Qho. #ESMO25 #GynOnc #GynecologicCancers
More from this author
Explore content categories
- Career
- Productivity
- Finance
- Soft Skills & Emotional Intelligence
- Project Management
- Education
- Technology
- Leadership
- Ecommerce
- User Experience
- Recruitment & HR
- Customer Experience
- Real Estate
- Marketing
- Sales
- Retail & Merchandising
- Science
- Supply Chain Management
- Future Of Work
- Consulting
- Writing
- Economics
- Artificial Intelligence
- Employee Experience
- Workplace Trends
- Fundraising
- Networking
- Corporate Social Responsibility
- Negotiation
- Communication
- Engineering
- Hospitality & Tourism
- Business Strategy
- Change Management
- Organizational Culture
- Design
- Innovation
- Event Planning
- Training & Development
Very interesting